GLP1R and pancreatic neoplasm: Another meta-analysis of 43 randomized controlled trials demonstrated that GLP-1 receptor agonists (GLP-1 RAs) were not linked to pancreatic cancer (MH-OR 1.28 [0.87, 1.89]; p = 0.20) or pancreatitis [Mantel–Haenszel Odds Ratio (MH-OR) 1.24 [0.94, 1.64]; p = 0.13] [166].